Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | CASP3 | P42574 | 2/20 | 0.51 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.50 |
| ▸ | FABP7 | O15540 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | MDM4 | O15151 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31173373 | 1.00 | KMT2A (0.62) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL29728458 | 1.00 | KMT2A (0.62) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL21297386 | 0.89 | EPHX2 (0.55) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL402111 | 0.87 | KMT2A (0.68) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL21332462 | 0.86 | KMT2A (0.66) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL16253851 | 0.86 | KMT2A (0.51) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL20126921 | 0.86 | KMT2A (0.60) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL13993335 | 0.85 | KMT2A (0.58) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL1800381 | 0.85 | KMT2A (0.64) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL30238049 | 0.85 | KMT2A (0.64) | KMT2AEPHX2CASP3FABP5FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 315 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238458-A1 | COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF | PURDUE RESEARCH FOUNDATION | 2024-07-18 | — | — | US | disclosed |
| US-20240218342-A1 | SITE-SPECIFIC GLYCAN REMODELING OF LYSOSOMAL ENZYMES AND APPLICATIONS THEREOF | UNIVERSITY OF MARYLAND, COLLEGE PARK | 2024-07-04 | — | — | US | disclosed |
| EP-4389822-A1 | CROSSLINKABLE ACRYLIC RUBBER COMPOSITION | Unimatec Co., Ltd. (JP) | 2024-06-26 | — | — | EP | disclosed |
| CN-117279655-A | Pharmaceutical use of cyclic peptide compounds | 中外制药株式会社 | 2023-12-22 | — | — | CN | disclosed |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
| WO-2023234426-A1 | ANTIBODY-MULTIDRUG CONJUGATE | ＵＢＥ株式会社 | 2023-12-07 | — | — | WO | disclosed |
| US-11827920-B2 | Nanostructure, a biosensor including the nanostructure, and a screening method | POSTECH Research and Business Development Foundation (KR) | 2023-11-28 | — | — | US | disclosed |
| WO-2023225661-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-23 | — | — | WO | disclosed |
| EP-3508476-B1 | AMINO MERCAPTAN COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF IN PROTECTION AGAINST RADIATION | SHANGHAI KECHOW PHARMA INC (CN) | 2023-11-22 | — | — | EP | disclosed |
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20070078094-A1 | Guanidinium delivery carriers | NITTO DENKO CORPORATION (JP) | 2007-04-05 | — | — | US | disclosed |
| US-20070078094-A1 | Guanidinium delivery carriers | NITTO DENKO CORPORATION (JP) | 2007-04-05 | — | — | US | disclosed |
| US-20070072802-A1 | Peptide nucleic acid based guanidinium compounds | NITTO DENKO CORPORATION (JP) | 2007-03-29 | — | — | US | disclosed |
| US-20070010561-A1 | PRENYLATION INHIBITORS AND METHODS OF THEIR SYNTHESIS AND USE | PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC | 2007-01-11 | — | — | US | disclosed |
| US-7160735-B2 | Tagged microparticle compositions and methods | MONOGRAM BIOSCIENCES, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| EP-1724269-A1 | Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide - derivatives as factor Xa inhibitors | Sanofi-Aventis Deutschland GmbH (DE) | 2006-11-22 | — | — | EP | disclosed |
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-01-26 | — | — | US | disclosed |
| US-20040210041-A1 | Multimeric proteins for use in the treatment and detection of cell proliferative disorders | ARBOGAST CHRISTOPHE (FR) | 2004-10-21 | — | — | US | disclosed |
| US-20040072849-A1 | Dioxanes and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-04-15 | — | — | US | disclosed |
| CN-1343206-A | Cyclocompound | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-04-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | GIPR, GLP1R, GCGR | KMT2A 3040/4885EPHX2 2665/4885CASP3 1537/4885 |
| US-20240218342-A1 | SITE-SPECIFIC GLYCAN REMODELING OF LYSOSOMAL ENZYMES AND APPLICATIONS THEREOF | GAA, MAN2B1, M6PR | KMT2A 3330/4885EPHX2 3591/4885CASP3 4794/4885 |
| US-20070078094-A1 | Guanidinium delivery carriers | SLC2A9, SLC29A2, SLC2A4 | KMT2A 4242/4885EPHX2 2166/4885CASP3 3296/4885 |
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | ITGA4, ITGB4, ITGA1 | KMT2A 3460/4885EPHX2 4011/4885CASP3 2064/4885 |
| US-20240238458-A1 | COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF | FAP, FIBP, FGFR1 | KMT2A 4193/4885EPHX2 2557/4885CASP3 1444/4885 |
| US-20070010561-A1 | PRENYLATION INHIBITORS AND METHODS OF THEIR SYNTHESIS AND USE | FNTA, RCE1, GGPS1 | KMT2A 4201/4885EPHX2 1146/4885CASP3 4516/4885 |
| US-20040072849-A1 | Dioxanes and uses thereof | UTS2R, HDAC5, AMDHD2 | KMT2A 178/4885EPHX2 1101/4885CASP3 4036/4885 |
| US-20070072802-A1 | Peptide nucleic acid based guanidinium compounds | SLC29A1, SLC29A2, SLC28A1 | KMT2A 4167/4885EPHX2 4625/4885CASP3 3437/4885 |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | M6PR, ASGR1, IGF2R | KMT2A 2277/4885EPHX2 2827/4885CASP3 3970/4885 |
| US-20040210041-A1 | Multimeric proteins for use in the treatment and detection of cell proliferative disorders | MKI67, TP53, VHL | KMT2A 3846/4885EPHX2 4192/4885CASP3 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.